RediCare Presents Groundbreaking AI-Driven Lifestyle Intervention Findings at World Congress of Internal Medicine 2024

Prague, November 2024 

RediCare Control is proud to announce that our Consultant Cardiologist and Clinical Advisor, Dr. Niall Colwell, both chaired a key session and presented our latest clinical findings at the 37th World Congress of Internal Medicine (WCIM 2024) in Prague. Dr. Colwell presented our study, titled “Artificial Intelligence-Driven Lifestyle Change Positively Impacts Type II Diabetes and Prediabetes,” which showcased how AI can transform chronic disease management. 

This clinical study, involving 172 patients, demonstrates the power of AI-powered lifestyle interventions in improving the management of Type 2 diabetes (T2DM) and non-diabetic hyperglycaemia. Dr. Colwell’s presentation highlighted the significant improvements observed in patients over the course of a year, reinforcing the potential of AI to drive scalable solutions for chronic disease prevention and management. 

Key Study Results 

The study involved two cohorts: Type 2 Diabetes (T2DM) and Non-Diabetic Hyperglycemia (NDH). The results are below: 

Type 2 Diabetes (T2DM) Cohort: 

• 5.3% reduction in weight 

• 19.9% reduction in HbA1c 

• 45% of patients achieved normalized HbA1c levels 

Non-Diabetic Hyperglycemia (NDH) Cohort: 

• 6.5% reduction in weight 

• 6.7% reduction in HbA1c 

• 42% of patients reached normalized HbA1c levels 

These findings highlight the clinically significant impact of AI-driven lifestyle changes on both weight management and blood sugar control, demonstrating that such interventions can make a meaningful difference in the long-term management of Type 2 diabetes and prediabetes. 

A Scalable Solution for Chronic Disease Management 

Dr. Colwell’s presentation at WCIM 2024 underscores the potential of AI technology to not only support personalised lifestyle changes but also enable scalable solutions for managing chronic diseases such as (but not limited to) Type 2 diabetes and non-diabetic hyperglycaemia. By addressing the root causes of these conditions with evidence-based  interventions, RediCare is pioneering a new approach to chronic disease management that has the power to transform patient outcomes at scale. 

Dr. Colwell remarked: 

"It was a privilege to present our findings at WCIM 2024. Our study demonstrates the real-world impact that our intervention and AI can have on chronic disease management, and we are excited to continue leading the way in delivering personalised care, management and prevention through technology. These results are a significant step forward in improving patient outcomes at scale." 

 

About RediCare 

RediCare Control is a digitally delivered service with health coach support, designed to treat and prevent chronic conditions such as High Blood Pressure, Pre-Diabetes, Type 2 Diabetes, High Cholesterol, Polycystic Ovary Syndrome (PCOS), Non-Alcoholic Fatty Liver Disease (NAFLD), Obesity and Overweight conditions. 

RediCare Control is deeply integrated with primary care workflows and delivers clinically validated improvements in metabolic health which drives reductions in GP demand and significant savings via medication avoidance and secondary care health costs. 

To learn more about RediCare and how we are transforming healthcare, visit www.controldtx.com.